Navigation Links
For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission
Date:4/16/2009

Abbott/Eisai's Humira Will Earn Decision Resources' Clinical Gold Standard Status for Ulcerative Colitis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists identify a therapy's effect on induction of remission as the attribute that most influences their prescribing decisions in moderate to severe ulcerative colitis. Clinical data and the opinions of interviewed thought leaders indicate that corticosteroids have advantages in this attribute over Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade (infliximab), the sales-leading agent in the market.

The new report entitled Ulcerative Colitis: Opportunity Awaits Therapies That Treat Moderate to Severe Disease More Effectively Than Infliximab finds that a drug that maintains remission in a higher percentage of patients with moderate to severe ulcerative colitis than infliximab at one year would earn a 30 percent patient share in the United States and a 15 percent patient share in Europe, according to surveyed U.S. and European gastroenterologists.

In 2008, Decision Resources' proprietary clinical gold standard for ulcerative colitis was prednisone. Based on available data and expert opinion, Abbott/Eisai's Humira (adalimumab) will earn gold-standard status for ulcerative colitis in 2012, following its approval for the indication in 2011. Interviewed experts believe that adalimumab has potential to be superior in maintenance of remission when compared to infliximab.

"Although clinical trial data are limited, interviewed experts believe that adalimumab will be more effective than infliximab in the maintenance setting and that it offers superior safety and tolerability when compared with other drugs in the market, including infliximab," said Decision Resources Analyst Benjamin Guikema, Ph.D. "Adalimumab also has a reduced risk of major organ toxicity, giving it a significant advantage over all other currently available therapies."

About the Report

Ulcerative Colitis: Opportunity Awaits Therapies That Treat Moderate to Severe Disease More Effectively Than Infliximab is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                               Decision Resources, Inc.
    Christopher Comfort                              Elizabeth Marshall
    781-296-2597                                     781-296-2563
    ccomfort@dresources.com                          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New therapeutic targets in the treatment of ulcerative colitis
2. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
3. Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives
4. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
5. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
6. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
7. Study underway to find an alternative cure for Crohns disease and ulcerative colitis
8. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
9. Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis?
10. Companies Pay a High Price for Employees With Crohns Disease and Ulcerative Colitis, According to Study From Thomson Reuters
11. Identification of genetic markers for ulcerative colitis could lead to treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... ... In a part of the city where’s it’s easy to spot the neon lights of ... hoping to attract diners with a taste for real food. , On May 13, ... Cornerstone Grill, an urban casual restaurant focusing on dishes made by hand with wholesome, organic ...
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. Inc ., ... it has been recognized as one of the best small businesses for new dads ... one of nine small businesses providing progressive benefits to new parents on the organization’s ...
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... stories, which come courtesy of leaders in the nursing and health care industry. It ... advocates and associations—namely Abilene Christian University. , As the nursing industry is coming ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways ... and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. ... say grilling is their favorite way to cook a hot dog, far outpacing other ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today ... test for wounds and infections. This test ensures ... and select viruses. The test requires only a ... David G. Bostwick , MD, ... to facilitate wound healing: "We are excited to ...
Breaking Medicine Technology: